These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 37691228)

  • 1. The Common Denominators of Parkinson's Disease Pathogenesis and Methamphetamine Abuse.
    Vincent B; Shukla M
    Curr Neuropharmacol; 2024; 22(13):2113-2156. PubMed ID: 37691228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of α-Synuclein in Methamphetamine-Induced Neurotoxicity.
    Wu M; Su H; Zhao M
    Neurotox Res; 2021 Jun; 39(3):1007-1021. PubMed ID: 33555547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson's disease.
    Shin EJ; Jeong JH; Hwang Y; Sharma N; Dang DK; Nguyen BT; Nah SY; Jang CG; Bing G; Nabeshima T; Kim HC
    Arch Pharm Res; 2021 Jul; 44(7):668-688. PubMed ID: 34286473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2012 Nov; 53(9):1791-806. PubMed ID: 22967820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-Nitrosylating protein disulphide isomerase mediates α-synuclein aggregation caused by methamphetamine exposure in PC12 cells.
    Wu XF; Wang AF; Chen L; Huang EP; Xie WB; Liu C; Huang WY; Chen CX; Qiu PM; Wang HJ
    Toxicol Lett; 2014 Oct; 230(1):19-27. PubMed ID: 25090657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methamphetamine-induced neurotoxicity: the road to Parkinson's disease.
    Thrash B; Thiruchelvan K; Ahuja M; Suppiramaniam V; Dhanasekaran M
    Pharmacol Rep; 2009; 61(6):966-77. PubMed ID: 20081231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methamphetamine and heightened risk for early-onset stroke and Parkinson's disease: A review.
    Lappin JM; Darke S
    Exp Neurol; 2021 Sep; 343():113793. PubMed ID: 34166684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methamphetamine binds to α-synuclein and causes a conformational change which can be detected by nanopore analysis.
    Tavassoly O; Lee JS
    FEBS Lett; 2012 Sep; 586(19):3222-8. PubMed ID: 22771474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methamphetamine induced neurotoxic diseases, molecular mechanism, and current treatment strategies.
    Shrestha P; Katila N; Lee S; Seo JH; Jeong JH; Yook S
    Biomed Pharmacother; 2022 Oct; 154():113591. PubMed ID: 36007276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial oxidant stress mediates methamphetamine neurotoxicity in substantia nigra dopaminergic neurons.
    Graves SM; Schwarzschild SE; Tai RA; Chen Y; Surmeier DJ
    Neurobiol Dis; 2021 Aug; 156():105409. PubMed ID: 34082123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is methamphetamine abuse a risk factor in parkinsonism?
    Guilarte TR
    Neurotoxicology; 2001 Dec; 22(6):725-31. PubMed ID: 11829406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease.
    Haque ME; Akther M; Azam S; Kim IS; Lin Y; Lee YH; Choi DK
    Br J Pharmacol; 2022 Jan; 179(1):23-45. PubMed ID: 34528272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference targeting α-synuclein attenuates methamphetamine-induced neurotoxicity in SH-SY5Y cells.
    Chen L; Huang E; Wang H; Qiu P; Liu C
    Brain Res; 2013 Jul; 1521():59-67. PubMed ID: 23688541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson's Disease.
    Sohrabi T; Mirzaei-Behbahani B; Zadali R; Pirhaghi M; Morozova-Roche LA; Meratan AA
    J Mol Biol; 2023 Jun; 435(12):167992. PubMed ID: 36736886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders.
    Callaghan RC; Cunningham JK; Sajeev G; Kish SJ
    Mov Disord; 2010 Oct; 25(14):2333-9. PubMed ID: 20737543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic Impact of Fatty Acid-Binding Proteins in Parkinson's Disease-Potential Biomarkers and Therapeutic Targets.
    Kawahata I; Fukunaga K
    Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
    Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
    J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of preconditioning with low dose of LPS on paraquat-induced neurotoxicity, microglia activation and expression of α-synuclein and synphilin-1 in the dopaminergic system.
    Kuter KZ; Śmiałowska M; Ossowska K
    Pharmacol Rep; 2022 Feb; 74(1):67-83. PubMed ID: 34762280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between methamphetamine and environmental stress: role of oxidative stress, glutamate and mitochondrial dysfunction.
    Tata DA; Yamamoto BK
    Addiction; 2007 Apr; 102 Suppl 1():49-60. PubMed ID: 17493053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.